Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy.

• Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies- an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. 

• Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in leadership roles of increasing responsibility. 

• Enovis' second-quarter net sales of $525 million increased 23% on a reported basis and 5% on a comparable sales basis over the same quarter in 2023. 

• The second-quarter results show solid execution in P&R, robust growth in International Recon, and the addition of two recent acquisitions, Lima and Novastep. Compared to the same quarter in 2023, Recon's net sales increased by 60% on a reported basis, with 7% growth in comparable sales, while P&R increased by 2% on a reported basis and 3% in comparable sales.

• Enovis also announced a second-quarter net loss from continuing operations of $18 million, or 3.5% of reported sales, and adjusted EBITDA of $90 million, or 17.2% of reported sales, up 190 basis points from the comparable prior-year period.

Acrobull UK Recommendation Based on Evaluation